论文部分内容阅读
脾肿大是 ALL 的一种常见表现,ALL 初发期出现脾大是肿瘤增长的反映,对于患儿则提示较差的预后。获得血液学完全缓解的病人出现脾大,临床上须和白血病复发相鉴别。最近,有人报告缓解期 ALL患儿出现脾大未必由白血病浸润引起,认为脾脏足一抗白血病的保护性宿主反应源,患儿施行脾切除可促使复发。作者对101例成人 ALL 患者,在确诊时和缓解期的脾肿大发生率,其预后的意义和脾切除对存活率的影响作了探讨。101例初发 ALL 患者,男59例,女42例,15～78岁,平均29.1岁。诱导治疗药物包括强的松、长春新硷和 anthracycline,对于严重者加用环磷酰胺。均鞘内注射氨甲喋呤作中枢神经系统(CNS)预防。
Splenomegaly is a common manifestation of ALL, ALL sprouting occurs at the initial stage of the tumor is a reflection of tumor growth, suggesting a poor prognosis for children. Obtained hematology complete remission in patients with splenomegaly, clinically and leukemia relapse phase identification. Recently, it was reported remission ALL children with splenomegaly may not be caused by leukemia infiltration, that the spleen of a protective leukemia protective host response source, splenectomy in children can promote recurrence. The authors investigated the incidence of splenomegaly in 101 adults with ALL at diagnosis and in remission, the significance of their prognosis and the effect of splenectomy on survival. 101 cases of patients with initial ALL, 59 males and 42 females, aged 15 to 78 years, mean 29.1 years. Induction treatments include prednisone, vincristine and anthracycline, with cyclophosphamide in severe cases. Intrathecal injection of methotrexate for the central nervous system (CNS) prevention.